Can PledPharma safely reduce the serious side effects of chemotherapy treatment?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Can PledPharma safely reduce the serious side effects of chemotherapy treatment?
Released on: October 22, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In the USA alone more than 500,000 doses of chemotherapy are used in treatment of colorectal cancer per year and many chemotherapy treatments cannot be completed as planned due to serious side effects.
  • Summary
  • Transcript
  • Participants
  • Company
In the USA alone more than 500,000 doses of chemotherapy are used in treatment of colorectal cancer per year and many chemotherapy treatments cannot be completed as planned due to serious side effects. Jacques Nasstrom, CEO of Swedish company PledPharma reveals to Fintan Walton how they are focused on developing a new medicine PledOx® that reduces the severe side effects, which occur as a result of chemotherapy treatment. He also explains how they are funding and financing their clinical trails through partnering in order to take their developments to completion.
In the USA alone more than 500,000 doses of chemotherapy are used in treatment of colorectal cancer per year and many chemotherapy treatments cannot be completed as planned due to serious side effects. Jacques Nasstrom, CEO of Swedish company PledPharma reveals to Fintan Walton how they are focused on developing a new medicine PledOx® that reduces the severe side effects, which occur as a result of chemotherapy treatment. He also explains how they are funding and financing their clinical trails through partnering in order to take their developments to completion.
Jacques Nasstrom
PledPharma
Jacques Näsström has a basic training as Pharmacist with PhD in Pharmacology from Uppsala University and a Business degree from Stockholm School of Economics. He has more than 25 years of experience from the pharmaceutical and biotechnology industries, including a position as Investment Manager at Karolinska Investment Fund, and various positions within drug discovery at Astra and AstraZeneca and most recently as Director of Research & Development at Q-Med AB from 2006-2010.
PledPharma
PledPharma is a Swedish pharma company, which develops new treatments for life-threatening diseases. We are focused on developing a new medicine PledOx® that reduces the severe side effects, which occur as a result of chemotherapy treatment, and on evaluating an existing medicine’s ability to limit the damages on the heart that remain after acute myocardial infarction is treated with coronary angioplasty. Our projects meet significant medical needs and we have the opportunity to offer patients valuable supportive treatments in serious life-threatening diseases where there is also an opportunity for faster registration process with the FDA called “Breakthrough therapy”. This means that we also have the potential of offering our shareholders strong returns on investment. PledPharma (STO:PLED) is listed on NASDAQ OMX First North.